Sapreme Therapeutics announces oral presentation of new preclinical data on lead Duchenne muscular dystrophy candidate SPM-2551 at OTS 2026
- SPM-2551 demonstrated robust and durable pharmacological activity following a single low-dose administration in preclinical Duchenne muscular dystrophy (DMD) models
- Data support Sapreme’s proprietary SPT platform, designed to overcome endosomal entrapment and enable intracellular delivery of RNA therapeutics
- “We believe these data are unprecedented in the field, showing superior efficacy after only a single, low dose, beyond any of the existing data of marketed therapies and programs currently in development.” Marco Timmers, Chief Executive Officer
Utrecht, Netherlands – 14 October 2026: Sapreme Therapeutics (“Sapreme” or the “Company”), a biotechnology company developing next-generation RNA therapeutics for patients with genetically driven diseases, today announces the oral presentation of new preclinical data from its lead Duchenne muscular dystrophy (DMD) programme, SPM-2551, at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), taking place in Denver, Colorado, US.
